medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2015, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2015; 13 (2)

Dermatofibrosarcoma protuberans: a review

González MEM, Lacy NRM, Boeta ÁL, Vega MME

Language: Spanish
References: 40
Page: 149-158
PDF size: 250.29 Kb.


ABSTRACT

Dermatofibrosarcoma protuberans (dfsp) is a fibrohistiocytic tumor with invasive behavior and high rates of local recurrence but with slow growth. Although it may be suspected clinically, the diagnosis is histopathologic and must be supplemented with immunohistochemistry. The treatment of choice is surgery, Mohs micrographic surgery is recommended and its prognosis depends on several factors such as patient age, topography, size (larger than 5 cm), recurrence and high mitotic rate (more than 10 mitoses per field 10x). The spread is hematogenous with lung metastases in 2-4% of cases.


REFERENCES

  1. Criscione, V.D. y Weinstock, M.A., “Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002”, J Am Acad Dermatol, 2007, 56: 968-973.

  2. Llombart, B., Serra-Guillén, C., Monteagudo, C., López Guerrero, J.A. y Sanmartín, O., “Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management”, Seminars in Diagnostic Pathology, 2013, 30, 13-28.

  3. Gloster, H.M., Jr., “Dermatofibrosarcoma protuberans”, J Am Acad Dermatol, 1996, 35: 355-374.

  4. Serra-Guillén, C., Llombart, B. y Sanmartín, O., “Dermatofibrosarcoma protuberans”, Actas Dermosifiliogr, 2012, 103 (9): 762-777.

  5. Edelweiss, M. y Malpica, A., “Dermatofibrosarcoma protuberans of the vulva: a clinico pathologic and immunohistochemical study of 13 cases”, Am J Surg Pathol, 2010, 34: 393.

  6. Gooskens, S.L., Oranje, A.P., Adrichem, A.N.A., Waard-Van, F.B., Hollander, J.C., Van de Ven, C.P. et al., “Imatinib mesylate for children with dermatofibrosarcoma protuberans”, Pediatr Blood Cancer, 2010, 55: 369-373.

  7. Tsai, Y.-J., Pao-Yuan, Lin, Khong-Yik, Chew y Yuan-Cheng, Chiang, “Dermatofibrosarcoma protuberans in children and adolescents: Clinical presentation, histology, treatment, and review of the literature” Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014, http://dx.doi. org/ 10.1016/j.bjps.2014.05.031.

  8. Llombart, B., Sanmartín, O. y López Guerrero, J.A., “Dermatofibrosarcoma protuberans en la infancia”, Piel, 2006, 21: 435-441.

  9. Sanmartín, O., Llombart, B., López Guerrero, J.A. et al., “Dermatofibrosarcoma protuberans”, Actas Dermosifiliogr, 2007, 98: 77-87.

  10. Lautier, R., Wolff, H.H. y Jones, R.E., “An immunohistochemical study of dermatofibrosarcoma protuberans supports its fibroblasticcharacter and contradicts neuroectodermalor histiocytic components”, Am J Dermatopathol, 1990, 12: 25-30.

  11. Allan, A.E., Tsou, H.C., Harrington, A., Stasko, T., Lee, X., Si, S.P. et al., “Clonalorigin of dermatofibrosarcoma protuberans”, J InvestDermatol, 1993, 100: 99-102.

  12. Bowne, W.B., Antonescu, C.R., Leung, D.H. et al., “Dermatofibrosarcoma protuberans: A clinico pathologic analysis of patients treated and followed at a single institution”, Cancer, 2000, 88: 2711.

  13. The esmo (European Sarcoma Network Working Group), “Softt issue and visceral sarcomas: esmo Clinical Practice Guidelines for diagnosis, treatment and follow-up”, Annals of Oncology, 2012, 23 (Supplement 7): 92-99.

  14. Zelger, B., Sidoroff, A., Stanzl, U., Fritsch, P.O., Ofner, D., Zelger, B. et al., “Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinico pathologic comparison”, Am J Surg Pathol, 1994, 18: 677-686.

  15. Weedon, D., Weedon’s skin pathology, 3ª ed., Elsevier, 2010, cap. 34: 833- 835.

  16. Abenoza, P., Lillemoe T: cd34 and factor xiiia in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans”, Am J Dermatopathol, 1993, 15: 429-434.

  17. West, R.B., Harvell, J., Linn, S.C., Liu, C.L., Prapong, W., Hernández-Boussard, T. et al., “Apo D in softt tissue tumors: a novel marker for dermatofibrosarcoma protuberans”, Am J Surg Pathol, 2004, 28: 1063-1069.

  18. Abbott, J.J., Oliveira, A.M. y Nascimento, A.G., “The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans”, Am J Surg Pathol, 2006, 30: 436-443.

  19. Ahmed, A.A., Ostlie, D., Fraser, J., Newell, B. y Cooley, L., “Dermatofibrosarcoma protuberans in the breast of a 2-year-old girl”, Ann Diag Pathol, 2010, 14: 279-283.

  20. Pedeutour, F., Simon, M.P., Minoletti, F. et al., “Translocation t(17; 22) (q22;q13) in dermatofibrosarcoma protuberans: a new tumor associated chromosomere arrangement”, Cytogenet Cell Genet, 1996, 72: 171-174.

  21. Sang Yun, Ha et al., dfsp rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications”, Human Pathology, 2013, 44: 1300-1309.

  22. Bianchini, L., Maire, G., Guillot, B. et al., “Complex t(5;8) involving the cspg2 and ptk2b genes in a case of dermatofibrosarcoma protuberans without the col1a1-pdgfb fusion”, Virchows Arch, 2008, 452: 689-696.

  23. Llombart, B., Monteagudo, C., Sanmartín, O., López-Guerrero, J.A., Serra-Guillén, C., Poveda, A., Jorda, E. et al., “Dermatofibrosarcoma protuberans: A clinico pathological, immunohistochemical, genetic (col1a1-pdgfb), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors”, J Am Acad Dermatol, 2011, 65: 564-575.

  24. Serra-Guillén, C., Sanmartín, O., Llombart, B. et al., “Correlation between preoperative magnetic resonance imaging and surgical margins with modified Mohs for dermatofibrosarcoma protuberans”, Dermatol Surg, 2011, 37: 1638-1645.

  25. National Comprehensive Cancer Network, “Dermatofibromasarcoma protuberans”, 2014, http://www.nccn.org/professionals/physician_ gls/pdf/dfsp.pdf.

  26. Khatri, V.P., Galante, J.M., Bold, R.J., Schneider, P.D., Ramsamooj, R., Goodnight, Jr, J.E., “Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment”, Ann Surg Oncol, 2003, 10: 1118-1122.

  27. Bowne, W.B., Antonescu, C.R., Leung, D.H. et al., “Dermatofibrosarcoma protuberans: a clinico pathologic analysis of patients treated and followed at a single institution”, Cancer, 2000, 88: 2711-2720.

  28. Rutgers, E.J., Kroon, B.B., Albus-Lutter, C.E. y Gortzak, E., “Dermatofibrosarcoma protuberans: treatment and prognosis”, Eur J Surg Oncol, 1992, 18: 241-248.

  29. Loghdey, S., Varma, S., Rajpara, S., Al-Rawi, H., Perks, G. y Perkins, W., “Mohs micrographic surgery for dermatofibrosarcoma protuberans (pdgf): A single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature”, Journal of Plastic, Reconstructive & Aesthetic Surgery, 2014, http://dx.doi. org/10.1016/j.bjps.2014.05.021.

  30. Paradisi, A., Abeni, D., Rusciani, A., Cigna, E., Wolter, M., Scuderi, N. et al., Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographicsurgery”, Cancer Treat Rev, 2008, 34: 728-736.

  31. Buck, D., Kim, J., Alam, M., Rawlani, W., Johnson, S., Connor, C., Dumanian, G. y Wayne, J., “Multidisciplinary approach to the management of dermatofibrosarcoma protuberans”, J Am Acad Dermatol, 2012, 67: 861-866.

  32. Dagan R, Morris CG, Zlotecki RA, et al., “Radiotherapy in the treat-ment of dermatofibrosarcoma protuberans”, Am J Clin Oncol, 2005,28:537.539

  33. Castle, K., Guadagnolo, B., Tsai, C., Feig, B. y Zagars, G., “Dermatofibrosarcoma protuberans: Long-term outcomes of 53 Patients Treated with Conservative Surgery and Radiation Therapy”, Int J Radiation Oncol Biol Phys, 2013, 86: 585-590.

  34. Lindner NJ, Scarborough MT, Powel GJ, et al.,”Revisión surgery in dermatofibrosarcoma protuberans of the trunk and extremities”,Eur J Surg Oncol, 1999; 25:392

  35. Van der Graaf, W. y Gelderblom, H., “New Systemic Therapy Options for Advanced Sarcomas”, Current Treatment Options in Oncology, 2012, 13: 306–317.

  36. Lemm, D., Mugge, L.O., Mentzel, T. y Höffken, K., “Current treatment options in dermatofibrosarcoma protuberans”, J Cancer Res Clin Oncol, 2009, 135: 653-655.

  37. McArthur, G.A., “Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease”, J Natl Compr Canc Netw, 2007, 5: 557-562.

  38. Rutkowski, P., Van Glabbeke, M., Rankin, C.J. et al., Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase ii clinical trials”, J Clin Oncol, 2010, 28: 1772–1779.

  39. Pretel-Irazabal, M., Tuneu-Valls, A. y Ormaechea, N., “Efectos adversos cutáneos del imatinib (inhibidor de la tirosíncinasa)”, Actas Dermosifiliogr, 2013, http://dx.doi.org/10.1016/j.ad.2013.01.009.

  40. http://economia.gob.mx/transparencia/transparenciafocalizada/precios_ max_medicamentos_patente_2014_0111.




2020     |     www.medigraphic.com